Ignite Creation Date:
2024-05-05 @ 10:32 PM
Last Modification Date:
2024-10-26 @ 10:20 AM
Study NCT ID:
NCT01127555
Status:
COMPLETED
Last Update Posted:
2013-10-08
First Post:
2010-05-05
Brief Title:
Salvage mFOLFOX in BTC After Failure of Gemcitabine
Sponsor:
Chung-Ang University
Organization:
Chung-Ang University
Study Overview
Official Title:
Phase II Study of Salvage mFOLFOX5-fluorouracil Leucovorin Oxaliplatin in Patients With Unresectable Biliary Tract Cancer BTC Who Had Failed Gemcitabine
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of mFOLFOX 5-fluorouracil leucovorin oxaliplatinas salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None